SUMMARY A randomised clinical trial of single dose trimethoprim against a seven day course of co-trimoxazole (trimethoprim/sulphamethoxazole) for the treatment of uncomplicated urinary tract infection was carried out in 106 children aged between 2 and 16 years. Of the 50 children with confirmed urinary tract infections who were followed up 48 hours after treatment with a single dose of trimethoprim all were free of infection, whereas two of the 56 who received the course of co-trimoxazole (4%) had persisting infections. At follow up after 10 days, however, significantly more of the group treated with trimethoprim had evidence of recurrent urinary tract infection compared with those who had received co-trimoxazole (10 of 44, 23%, compared with one of 46, 2%). Of the recurrences in the trimethoprim group, six were asymptomatic.
The use of a single dose or a single day of treatment for uncomplicated urinary tract infections in children has obvious attractions.1 These include improved compliance, more rapid resolution of symptoms, less risk of side effects, and reduced cost.Lp Previous reports have suggested that a single dose is equally as effective as a longer course, but recent reappraisal has raised the question of inadequate sample size and the committing of the Type II error-the false assumption that the two treatments were equally effective when too few patients had been studied to be sure that even quite larfe differences had not been missed by chance.45 Moffat et al concluded after reviewing published clinical trials in children that there was insufficient evidence to advocate the use of short courses of treatment for urinary tract infections (Moffat M. Short course antibiotic therapy of urinary tract infections in children. Presented at the Annual Scientific Meeting of the Ambulatory Pediatric Association, Washington DC, May 1986 ). An additional problem is that early recurrence of infection may be more likely to occur after single dose treatment. 6 Many antibiotics have been used in single dose treatment. Several trials have evaluated trimethoprim alone in the treatment of adult urinary tract infections, and concluded that it was as effective as co-trimoxazole (trimethoprim/sulphamethoxazole) when used in conventional courses. [7] [8] [9] The rationale for the use of trimethoprim without sulphamethoxazole is the decreased risk of side effects,9 the reduced risk of the development of resistance,1O the reduced cost, and the elimination of an unnecessary drug from the regimen.11 No comparison that we know of has been made of trimethoprim and co-trimoxazole, nor has trimethoprim been used as a single dose in the treatment of uncomplicated urinary tract infections.
Our hypothesis was that in children and adolescents a single dose of trimethoprim was no less effective than a seven day course of co-trimoxazole in the early eradication of urinary tract infection, reducing the risk of early recurrence, and achieving early resolution of symptoms.
Patients and methods
Patients studied were outpatients presenting to the primary care or emergency departments of the Royal Children's Hospital. They were entered into the trial if they had a urinary tract infection on clinical assessment or microscopic examination of the urine, or both. Informed consent was obtained from the parents, and the following were excluded: those known or thought to be sensitive to sulphonamides, those with persistent vomiting or any other reason for not being able to tolerate oral treatment, those with ileostomies or ureterostomies, those already on antimicrobial treatment, and those aged less than 6 months.
A total of 254 patients were eligible, and were 581 582 Nolan, Lubitz, and Oberklaid randomised in blocks within strata related to age (6-47 months, 48 months or older) and whether or not they had had previous urinary tract infections. Of these, 138 (54%) were subsequently excluded because urinary tract infection was not confirmed by culture (n=112), they failed to attend for follow up (n=9), the organism cultured was resistant to trimethoprim or sulphamethoxazole (n=8), they were entered into the study more than once (n=7), or they were unable to take the drugs (n=2). The characteristics of the remaining 116 patients are shown in table 1. All but one patient in each group had symptoms including nausea, vomiting, urgency, Confirmation of the diagnosis required a growth of more than 108 colonies/l in a midstream specimen of urine, or any growth from a suprapubic aspirate. Absence of infection was confirmed by a growth of less than 107 colonies/l from a midstream or bag specimen, or a sterile suprapubic aspirate. A mixed growth of organisms of 10 colonies/l or more was considered to be indeterminate, as was a pure growth of i07 colonies/l or more from a bag specimen. Those with uncertain diagnoses were withdrawn from further analysis, and when these occurred at follow up they were recorded as missing values (fig 1). There were no significant differences between the groups in the type of organisms isolated at the time of entry into the study, the most common organisms being Escherichia coli (75%), Klebsiella spp (5%), and Proteus spp (3%).
Trimethoprim was prepared as a powder from 300 mg tablets supplied by the manufacturer and given at the time of randomisation according to the regimen given in Single dose trimethoprim for urinary tract infection 583 to be taken at home, and the parents were instructed to start the treatment immediately.
Patients were seen 48 hours and 10 days after randomisation and had further specimens of urine taken. All those who had not previously had a radiograph of the urinary tract had an intravenous pyelogram. In addition, those aged 7 years or younger had a micturating cystourethrogram one to three weeks after diagnosis. The study was carried out before renal ultrasonography had become a routine investigation.
Statistical analysis was by the Mantel-Haenszel test, and estimates of the risk ratio and its 95% confidence interval were calculated for infection rates in the single dose group compared with the seven day treatment.12 1 Assignment strata (age and past history or urinary tract infection) were used. The 95% confidence intervals were calculated for the difference in risk of recurrence.
Results
The results of treatment are shown in table 3. Of the 50 patients with confirmed urinary tract infections who received a single dose of trimethoprim all were free of infection after 48 hours, whereas two of 56 (4%) of those who were receiving a seven day course of co-trimoxazole still had evidence of infection (p=0-26, 95% confidence interval on the difference -9% to 1%). One of the two children None of the patients who had recurrences had had loin tenderness or fever at the initial presentation.
Two thirds of the children who entered the study with confirmed urinary tract infections had not previously had infections, and eight of the 10 recurrences in the single dose group were in patients who had not previously had urinary tract infections. The child who had a recurrence in the cotrimoxazole group had had previous urinary tract infections.
More patients in the single dose group were symptom free or improved by the 48 hour follow up (47/50, 94%, compared with 46/56, 82%; p=0-05). There was, however, no difference between the groups in those who were totally symptom free (61% and 62%, respectively, p=0-92). Of the 10 children who had recurrences in the trimethoprim We do not know whether the higher risk of recurrence is caused by inadequately treated (perhaps parenchymal) infection, or reinfection with the same or a different organism.
" If the risk of recurrence is associated with a more established infection, a rapid diagnostic test to determine whether the patient has infection of the upper or lower renal tract could permit selective treatment with a single dose. Such a test, however, is not available. As none of the patients who had recurrences had both fever and loin tenderness at presentation one could speculate that reinfection rather than relapse was the most likely. Because of the unreliability of these clinical signs in localising the site of infection, however, firm conclusions cannot be drawn. It is noteworthy that the recurrences were mainly in children who had not previously had urinary tract infections, and who did not have structural abnormalities.
From these results it could be argued that trimethoprim without sulphamethoxazole is less effective than the combination. There were, however, no signs of urinary tract infection in patients in the trimethoprim group at 48 hours. In addition, it is doubtful whether synergy between trimethoprim and sulphamethoxazole is possible at the concentrations that can be achieved in urine. 16 Because the inhibitory action of sulphamethoxazole is dependent on the size of the inoculum it takes several cycles of cell growth to exhaust the microbial folate supplies, whereas trimethoprim causes rapid deprivation of the thymidilate supply to the organisms leading to the abrupt termination of folate synthesis. It is therefore probable that if there is any therapeutic effect from a single dose of co-trimnoxazole, it will be from the trimethoprim component.1" 17 Because of a flaw in the design of the study it is difficult to interpret the differences in recurrence rates. Because the urine was cultured 48 hours and 10 days after treatment was started rather than after it had finished, we could have underestimated the recurrence rate in the co-trimoxazole group. The recurrence rate in the single dose group of 23%, however, remains striking, and evidence from other trials suggests that an unbiased rate would still have been far below that in the single dose group.2 6 1821 The average recurrence rate in these six studies in patients given conventional courses was 9%.
Further data extracted from these studies provide additional evidence that single dose treatment is more likely to be associated with early recurrence. Fig 2 shows 
